PBAC recommends two RSV vaccines for older patients

RSV vaccination can cost $300 on the private market.

The PBAC wants two respiratory syncytial virus vaccines listed on the National Immunisation Program for older patients.

Published on Friday, the PBAC’s July meeting outcomes support taxpayer funding for GSK’s Arexvy and Pfizer’s Abrysvo for all patients aged 75 and older, as well as Aboriginal and Torres Strait Islander people aged 60-74.

Vaccination costs roughly $300 on the private market.

The PBAC already recommended a National Immunisation Program (NIP) listing for Abrysvo for older patients at its November meeting but had urged Pfizer to provide a better cost–benefit analysis, as well as more data on protection duration.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .